
    
      This is a first-in-human (FIH), multicenter, non-randomized, open-label, phase 1 study
      evaluating AMG 397 administered orally once weekly, as part of a 28-day treatment cycle in
      adult subjects with selected relapsed or refractory hematological malignancies
    
  